Sun Pharmaceutical Industries announced that INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U. S.
INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U. S. Food and Drug Administration (FDA) in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)